

Electronic Acknowledgement Receipt

EFS ID:	6688439
Application Number:	10607623
International Application Number:	
Confirmation Number:	7907
Title of Invention:	Method of treating acute myocardial infarction
First Named Inventor/Applicant Name:	Haim D. Danenberg
Customer Number:	75004
Filer:	SONJA KEENAN
Filer Authorized By:	
Attorney Docket Number:	92114.005US1
Receipt Date:	22-DEC-2009
Filing Date:	27-JUN-2003
Time Stamp:	14:05:21
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$ 180
RAM confirmation Number	433
Deposit Account	504387
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Transmittal Letter	92114_005US1_Transmittal_Letter_December_2009.pdf	514028 c1ae547c5e689c15a3bb53865ce87caa78d8d1	no	4
Warnings:					
Information:					
2	Information Disclosure Statement (IDS) Filed (SB/08)	92114_005US1_1449A_December_2009.pdf	135545 8113647a1b162ebba3c3cd9955439b085d8d1	no	1
Warnings:					
Information:					
This is not an USPTO supplied IDS fillable form					
3	Foreign Reference	WO96020698.pdf	5238958 adbf00f5ce8f18caaf660c3a3b1493bae516166f1	no	171
Warnings:					
Information:					
4	Foreign Reference	WO9716170.pdf	4512633 6890ce436e460199a29759945361bae3722eb	no	91
Warnings:					
Information:					
5	Information Disclosure Statement (IDS) Filed (SB/08)	92114_005US1_1449B_December_2009.pdf	373660 c5172c8be0f21173b6fd29b0c66eef3eef15	no	2
Warnings:					
Information:					
This is not an USPTO supplied IDS fillable form					
6	NPL Documents	Kramsch_Reference.pdf	1273394 3d0095d749c13a1353d6be213238957a0f14813	no	11
Warnings:					
Information:					
7	NPL Documents	Monkkonen_Reference_J_Drug_Target_1994.pdf	1796619 22201d30f0c48652817a228e91a3d95bce4db	no	10
Warnings:					
Information:					

8	NPL Documents	Donbrow_Reference_1992.pdf	20535872 7a0308cd978e08f1688a03bde8a3ca5c1891b92a	no	358
Warnings:					
Information:					
9	NPL Documents	Paspaliaris_Reference.pdf	490774 8ba3614971ad7670b8ba7d2145c09cb75f53c1da	no	7
Warnings:					
Information:					
10	NPL Documents	Van_Rooijen_Liposomes_Drug_Carrier_Chapter_9.pdf	854820 17ac7bde84b5d5530378442738dc03b85c72a8	no	15
Warnings:					
Information:					
11	NPL Documents	Thepen_Reference.pdf	1146871 363c2ef7c1de3d8a2c3e71ad6a7e731169115c	no	11
Warnings:					
Information:					
12	NPL Documents	Monkkonen_Reference_Pharm_a_Toxicol_1991.pdf	290740 ed17ca128874ac774bc38554294c58e8d5748c8f	no	3
Warnings:					
Information:					
13	NPL Documents	Van_Rooijen_Reference_Res_Immunol_1992.pdf	567412 4591142af729c724f53ab48cca758cd37c68019	no	3
Warnings:					
Information:					
14	NPL Documents	Biewenga_Reference_Cell_Tissue_Res_1995.pdf	1731892 6b1bdc736521f9168de8214b6d00673ae5c3e61	no	8
Warnings:					
Information:					
15	NPL Documents	Gaytan_Reference.pdf	790597 02304ab702144c14483177ad84e02705c3c4e259	no	9
Warnings:					
Information:					
16	NPL Documents	Van_Rooijen_Reference_Trends_Biotech_1997.pdf	1638865 d5141bf182c213697a1388ce8d691c78f5b79d4f	no	8
Warnings:					
Information:					

17	NPL Documents	Van_Rooijen_J_Leuk_Biol_1989.pdf	1050112 4b6d812ae0b0eb48137d445a03a18f1397c0b45	no	10
Warnings:					
Information:					
18	NPL Documents	Van_Rooijen_Seminars_Immunology_1992.pdf	818657 7d9707d617066c1a33a06de86f70c70539fc0b4	no	10
Warnings:					
Information:					
19	NPL Documents	Clodronate_Liposome_Printout.pdf	39165 eef4b4b4ef52b1e1c0b0c07f552c1775706b1eef070ec7	no	1
Warnings:					
Information:					
20	NPL Documents	Van_Rooijen_Reference_Virchows_1988.pdf	1112681 3c15bc890c87412debcdff53c5efec0a90bb43ac	no	5
Warnings:					
Information:					
21	NPL Documents	Van_Rooijen_J_Immun_Methods_1994.pdf	2467516 7a2a8200c2a6378c528a3bdf643423176709a238b	no	11
Warnings:					
Information:					
22	NPL Documents	Langer_Science_1990.pdf	2436869 751bb0bc11153a092136a24a935486186d0bdf4	no	8
Warnings:					
Information:					
23	NPL Documents	Cohen_Pharma_Res_1999.pdf	1211240 b62afca0b300f189721b6cd9b99ac2f8b63535	no	8
Warnings:					
Information:					
24	NPL Documents	11190787_Interview_Summary_November_2009.pdf	165773 17c0d49e196757004061c5665a899145cc080e	no	3
Warnings:					
Information:					
25	NPL Documents	Buiting_Reference.pdf	933999 60f9f4824c1aef15809a1535780c88bae933a0c4c	no	10
Warnings:					
Information:					

26	NPL Documents	Bergh_Reference.pdf	1461741 b74c0344859a3e6dc26308179ed0f3ca10f8e05	no	11
Warnings:					
Information:					
27	NPL Documents	Van_Rooijen_J_Immunol_Methods_1996.pdf	543586 3e7c0b20281cd0ba6d8775ac6431171d8387d36	no	7
Warnings:					
Information:					
28	NPL Documents	Leenaars_Reference.pdf	815995 8e3092ae642a106753b15d93e4031f5907d18f6f6	no	7
Warnings:					
Information:					
29	Fee Worksheet (PTO-875)	fee-info.pdf	29932 ad435e9802d8c5d58f7863d70c3e1170c586a6	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			54979946		
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><u>New Applications Under 35 U.S.C. 111</u></p> <p>If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><u>National Stage of an International Application under 35 U.S.C. 371</u></p> <p>If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><u>New International Application Filed with the USPTO as a Receiving Office</u></p> <p>If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					